Physician profile
Daniel Perl
NPI 1497133433
$9,346.08
in general payments reported to CMS, 2019-2025
29 companies · $2,211 in 2025
The $2,211 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $536 · 2022: $1,831 · 2023: $1,831 · 2024: $2,937 · 2025: $2,211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,962 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,961.87 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,104.65 | 2021-2025 | |
| Qol Medical, LLC | $1,029.52 | 2022-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $742.99 | 2022-2025 | Tremfya, Stelara |
| Regeneron Healthcare Solutions, INC. | $509.33 | 2022-2024 | Dupixent |
| Genzyme Corporation | $498.73 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $471.19 | 2022-2025 | Entyvio |
| Pfizer INC. | $412.69 | 2024-2025 | |
| Ardelyx, INC. | $386.42 | 2023-2025 | Ibsrela |
| Redhill Biopharma INC. | $296.53 | 2022-2024 | Talicia, Movantik, Aemcolo |
| Celgene Corporation | $293.28 | 2021-2024 | Zeposia |
| Braintree Laboratories, INC. | $289.02 | 2021-2025 | Sutab, Suflave |
| E.R. Squibb & Sons, L.L.C. | $264.99 | 2022-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $177.46 | 2023-2025 | Linzess |
| Lilly USA, LLC | $174.93 | 2023-2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $127.98 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $88.72 | 2024-2025 | Rezdiffra, Resmetirom |
| Celltrion USA INC. | $80.99 | 2024-2025 | Vegzelma, Zymfentra |
| Gilead Sciences, INC. | $77.47 | 2022-2024 | |
| Viiv Healthcare Company | $60.78 | 2022-2023 | Apretude |
| Nestle Healthcare Nutrition INC. | $45.14 | 2021 | |
| Phadia US INC. | $32.55 | 2022-2024 | Immunocap |
| Phathom Pharmaceuticals, INC. | $28.28 | 2025 | Voquezna |
| Shield Therapeutics INC | $26.09 | 2025 | |
| Galderma Laboratories, L.P. | $24.00 | 2024 | |
| Mayne Pharma Commercial LLC | $23.48 | 2022 | |
| Evoke Pharma, INC. | $23.03 | 2025 | |
| Oxford Immunotec USA INC | $21.85 | 2022 | |
| Capsovision, INC. | $20.11 | 2024 | Capsocam Plus |
| Alfasigma USA, INC. | $13.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Perl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.